Previous 10 | Next 10 |
NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders i...
NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders i...
NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders...
NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders...
2023-04-06 06:28:02 ET Summary Biogen and Eisa compared the effects of their drug Leqembi against the combined placebo decline rather than against the different rates of decline for APOE4 carriers and non-carriers. This made Leqembi look more effective for non-carriers than it act...
2023-03-30 08:10:53 ET Shares of Anavex Life Sciences ( NASDAQ: AVXL ) inched ~5% higher in the pre-market Thursday after announcing initial data from an open-label extension phase from its mid-stage trial for lead asset ANAVEX 2-73 in Parkinson's disease (PD) dementia. ...
Study successfully achieved both primary and secondary objectives ANAVEX®2-73 treatment resulted in improvements of all efficacy endpoints over 48 Weeks Anavex plans to proceed to ANAVEX®2-73 pivotal trial for Parkinson’s disease NEW YORK, March 30, 2023 (GL...
2023-03-16 04:06:18 ET Summary The ANAVEX2-73-AD-004 trial was mostly positive. A reputable journal article on the missing data would allay fears of a 'spin'. If the company's lead drug candidate did slow functional decline due to AD compared to the placebo, FDA approval is al...
2023-03-10 09:18:38 ET Summary Aricept, blarcamesine, simufilam, and panax ginseng by acting as acetylcholinesterase inhibitors and as indirect antioxidants, positively affecting cognition during the early stages of Alzheimer's disease. Simufilam performs about the same as Aricept...
NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders...
News, Short Squeeze, Breakout and More Instantly...
Anavex Life Sciences Corp. Company Name:
AVXL Stock Symbol:
NASDAQ Market:
Anavex Life Sciences Corp. Website:
2024-07-18 02:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsyc...
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsyc...